Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyA Sapino, F Montemurro, C Marchiò, et al.
Breast (Edinburgh, Scotland)|September 6, 2024
Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022A De Luca, M I Amabile, F Santori, et al.
The Journal of Pathology|May 20, 2008
Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breastC Marchiò, M Iravani, R Natrajan, et al.
The Journal of Pathology|September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER statusC Marchiò, R Natrajan, K K Shiu, et al.
Journal of Translational Medicine|May 15, 2024
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohortI Vanni, L Pastorino, V Andreotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyD Balmativola, C Marchiò, M Maule, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Pageof 2